Inhibition of Mitochondrial-Associated Protein MAGMAS Resensitizes Chemoresistant Prostate Cancer Cells to Docetaxel

This study examined a protein called MAGMAS in prostate cancer cells that are resistant to docetaxel (a common chemotherapy drug) compared to sensitive cells. MAGMAS levels were found to be much higher in the resistant cells. However, the reduction in MAGMAS levels in these resistant cells led to a noticeable drop in another protein called ABCB1, which helps cancer cells resist drugs. Additionally, resistant cells required more docetaxel or MAGMAS blocker, BT#9, to be affected compared to sensitive cells. However, when a low dose of BT#9 was used together with docetaxel, the resistant cells became more sensitive to docetaxel, needing lower concentrations to reduce cellular growth. In short, targeting MAGMAS with BT#9 could help make therapy-resistant prostate cancer cells respond better to docetaxel, providing a possible new way to tackle resistance to treatment.